Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- Toronto General HospitalToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT07902726
- Record updated
- 29 October 2026
- Original description
The study aims to determine the acute efficacy and safety of three sequential doses of acetazolamide (62.5 mg, 125 mg, 250 mg) each for 2 weeks in 20 patients with T2D receiving background SGLT2i therapy.Read full original descriptionShow less
Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes ('DIPPER') Pilot Study
The study aims to determine the acute efficacy and safety of three sequential doses of acetazolamide (62.5 mg, 125 mg, 250 mg) each for 2 weeks in 20 patients with T2D receiving background SGLT2i therapy.
Inclusion: Signed and dated written informed consent; Adult (≥18 years) at the time of consent; Established T2D diagnosis as per Diabetes Canada; HbA1c ≤10.0%; eGFR ≥45 ml/min/1.73m2; BP ≤160/90 and ≥90/60 mmHg; BMI 18.5-45.0 kg/m2; On stable dose of maximally tolerated RAASi for ≥30 days.
Exclusion: Use of carbonic anhydrase inhibitor in the 30 days prior to screening; Acute coronary syndrome, stroke or transient ischemic attack within 30 days prior to screening; Participation in another drug trial within 30 days of screening; Established diagnosis of type 1 diabetes as per Diabetes Canada; With known or suspected hypersensitivity or allergy to acetazolamide, dapagliflozin or related products; Untreated urinary or genital tract infection; Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome; Serum potassium <3.5 mmol/L; Serum bicarbonate <22 mEq/L; Liver disease (hepatic cirrhosis, alcohol/drug abuse ≥3 months, or serum AST, ALT, or total bilirubin >3X the upper limit of normal); Iodine intolerance; Severe glaucoma; Active pregnancy, breastfeeding or planning to become pregnant during study period; Patient not able to understand and comply with study requirements, based on Investigator's judgment.